Compare Quest Diagnostics Inc (DGX) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Intuitive Surgical, Inc. — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Intuitive Surgical, Inc. trades at $424 (market cap $146.76B). The key difference: Intuitive Surgical, Inc. is far larger — about 5.8× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Intuitive Surgical, Inc. for 84 Days on average.
| DGX | ISRG | |
|---|---|---|
Market Cap | $25.48B | $146.76B |
Volume | 941,866 | 2,529,814 |
Sector | Health | Health |
52-Week High | $247.45 | $592.85 |
52-Week Low | $173.49 | $332.02 |
Typical Hold Time | 56 Days | 84 Days |
Enterprise Value | $31.23B | $141.54B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
Intuitive Surgical (ISRG) trades at $423.96, up 2.28% with strong bullish momentum. The stock shows robust fundamentals with 2025 revenue reaching $10.06B and net income of $2.86B, maintaining 28.45% net margins. Recent quarters consistently beat EPS estimates, while technical indicators signal bullish moving averages. Analyst consensus remains strongly positive with 70% buy ratings and $480.78 price target, representing 13% upside potential.
ISRG's leadership in robotic surgery and expanding international presence in India and Japan provide growth catalysts, though China weakness and competitive pressures present risks. The stock's premium valuation (P/E 47.64) reflects high growth expectations, requiring continued execution. Current levels near resistance at $427 may test near-term momentum ahead of Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
